<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03496389</url>
  </required_header>
  <id_info>
    <org_study_id>Gabapentin ACLR</org_study_id>
    <nct_id>NCT03496389</nct_id>
  </id_info>
  <brief_title>Does Gabapentin Reduce Quadriceps Muscle Weakness After Anterior Cruciate Ligament Reconstruction?</brief_title>
  <official_title>Does Gabapentin Reduce Quadriceps Muscle Weakness After Anterior Cruciate Ligament Reconstruction? A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Authority, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Authority, Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anterior cruciate ligament (ACL) injury is a common sport injury in both professional and
      recreational athletes. Furthermore, persistent quadriceps weakness and wasting are frequently
      observed after anterior cruciate ligament reconstruction (ACLR). Several studies have
      demonstrated that muscular rehabilitation to normal strength is difficult, protracted, and
      often not achieved due to the inability to fully activate the quadriceps voluntarily. Pain
      and disuse are often blamed for the inhibition of muscle activation following joint injury.
      However, arthrogenic muscle inhibition (AMI) is often overlooked and not addressed. Thus, the
      magnitude of strength restoration of the quadriceps is frequently restricted despite solid
      rehabilitation protocols. As AMI is a reflex inhibition of musculature involving the
      neurotransmitter Î³-aminobutyrate (GABA), Gabapentin may have a potential role in modulating
      AMI, therefore limiting muscle weakness after ACLR.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in from baseline quadriceps muscle strength</measure>
    <time_frame>at postoperative 4, 6, 9, 12 months</time_frame>
    <description>Will be measured using Biodex isodex dynamometer to measure peak torque of knee extension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anterior-posterior knee stability</measure>
    <time_frame>at postoperative 4, 6, 9, 12 months</time_frame>
    <description>Measured by Lachman test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior-posterior knee stability</measure>
    <time_frame>at postoperative 4, 6, 9, 12 months</time_frame>
    <description>Measured by anterior drawer test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior-posterior knee stability</measure>
    <time_frame>at postoperative 4, 6, 9, 12 months</time_frame>
    <description>Measured by KT- 1000 knee arthrometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rotational laxity</measure>
    <time_frame>at postoperative 4, 6, 9, 12 months</time_frame>
    <description>Measured using the pivot shift test according to the IKDC score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>at postoperative 4, 6, 9, 12 months</time_frame>
    <description>Measured using single leg hop test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>at postoperative 4, 6, 9, 12 months</time_frame>
    <description>Measured using Lysholm knee scoring system</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Muscle Weakness</condition>
  <condition>Anterior Cruciate Ligament Rupture</condition>
  <arm_group>
    <arm_group_label>Gabapentin + panadol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol + panadol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin 300mg daily</description>
    <arm_group_label>Gabapentin + panadol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>Tramadol 50mg QID</description>
    <arm_group_label>Tramadol + panadol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panadol</intervention_name>
    <description>Panadol 500mg QID</description>
    <arm_group_label>Gabapentin + panadol</arm_group_label>
    <arm_group_label>Tramadol + panadol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-50

          2. Unilateral isolated ACL tear for primary ACLR confirmed clinically and radiologically

          3. No concomitant ligamentous, meniscal or chondral injuries.

        Exclusion Criteria:

          1. Concomitant multiple ligament injuries including posterior cruciate ligament, medial
             collateral ligament ligament, or lateral collateral ligament

          2. Concomitant meniscal injuries

          3. Concomitant chondral injuries

          4. preoperative radiographic signs of arthritis

          5. Revision ACL surgery

          6. Contralateral knee with

          7. Medical co-morbidities including Diabetes Mellitus, chronic renal failure

          8. Documented hypersensitivity to Gabapentin

          9. History of epilepsy

         10. History of depression

         11. Non-compliance to rehabilitation protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan P Ng, MBBCh MRCS</last_name>
    <phone>(852)53329291</phone>
    <email>ngjp2606@gmail.com</email>
  </overall_contact>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Authority, Hong Kong</investigator_affiliation>
    <investigator_full_name>Ng Jonathan Patrick</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rupture</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Paresis</mesh_term>
    <mesh_term>Anterior Cruciate Ligament Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

